Eli Lilly (LLY) executive says commercial access for Foundayo has been confirmed at two of the three largest US PBMs, effective mid-May

Eli Lilly securing commercial access for Foundayo with two of the largest US PBMs is a significant win that may enhance market penetration and revenue potential for the drug.

Newsquawk StaffPublished On the live feed at 9 more headlines followed before this page went public
Newsquawk headlinesUTC

Blue Owl (OWL) reiterates commitment to pay USD 0.92 dividend for 2026; continuing to see flows across credit platform

Bleecker Street Research announces a short on SharonAI (SHAZ)

Eli Lilly (LLY) executive says commercial access for Foundayo has been confirmed at two of the three largest US PBMs, effective mid-May

Valero (VLO) to run refineries up to 95% of capacity in Q2 2026; restarting large crude unit at Port Arthur Texas, expects refinery to return to "fairly normal rates" by May 1st

Russia's Defence Ministry says they have carried out a patrol over the neutral Barents and Norwegian seas

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This development not only validates their product's positioning but also suggests a positive trajectory for Eli Lilly's growth, which could influence investor sentiment and draw analyst attention. Keep an eye on how this affects sector peers and overall market momentum in the pharmaceuticals space.

Related headlines

The whole workspace, free to try.

Try it free